VERAXA Biotech AG, an emerging leader in designing novel cancer therapies, announced the initiation of cell line development for its lead BiTAC® T-cell engager (BiTAC-TCE)...
VERAXA Biotech AG, an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition...
